Elypta focuses on cutting-edge technology that uses liquid biopsies to detect early-stage cancer. Since its foundation Elypta has been developing the world’s first blood- and urine-test technology based on human metabolic biomarkers, for early detection and more frequent follow-up of cancer.
Founders: Francesco Gatto & Jens Nielsen
First year of investment: 2022
Focus area: Healthcare
CEO: Karl Bergman
Bonnier Responsible: Sofia Hasselberg, Elin Bäckman